Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs 10X Genomics Inc (TXG) Price & Performance

Mondelez International (MDLZ) trades at $60.39, up 1.7% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $0.73 exceeding expectations, supported by $38.54B revenue in 2025. Recent dividend increase to $0.52 per share and positive media coverage highlight management's confidence in cash flow stability. Valuation metrics include P/E of 22.22 and P/S of 1.97, trading below the consensus price target of $70.29.

MDLZ presents a compelling investment case with 76% analyst buy ratings and 16% upside to target, though cocoa cost pressures and margin compression from 13.76% in 2023 to 6.36% in 2025 pose near-term risks. The company's global brand portfolio and emerging market growth provide long-term stability, but investors should monitor commodity inflation's impact on profitability amid current neutral oscillator signals.

10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.

The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.